GlobeNewswire Inc | Mar 11, 2021 07:00AM EST

March 11, 2021

OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the Q1 Virtual Investor Summit.

Event Q1 Investor Summit Date March 23-25th, 2021 March 24th @ 3:00 PM ETPresentation Location https://zoom.us/webinar/register/ WN_y7LDL2ROTQqvz3iOVkINMw

About The Investor SummitThe Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.

To request complimentary investor registration: please visit the following website at www.investorsummitgroup.com

About AIM ImmunoTech Inc.AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development oftherapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Investor Relations Contact:Crescendo Communications, LLCPhone: 212-671-1021Email: aim@crescendo-ir.com

AIM ImmunoTech IncPhone: 800-778-4042Email: IR@aimimmuno.com

Investor Summit Contact:Brittney Blocker at brittney@investorsummitgroup.com

Wire Service ContactInvestorWire (IW) Los Angeles, Californiawww.InvestorWire.com212.418.1217 OfficeEditor@InvestorWire.com